The multiple myeloma drugs industry will relinquish an approximated estimate at a frequency of 12.2% for the projection space of 2021 to 2028 with factor such as higher prevalence of the patients suffering from multiple myeloma. The increase in R&D investment towards multiple myeloma also acts as a major factor for the growth of the multiple myeloma drugs market. Rising disposable income, increased awareness about immunotherapies and strategic initiatives by the market players has also given a boom to the U.S. multiple myeloma drugs market.
Robust presence of pipeline products and advancement in the technologies for diagnosis of multiple myeloma in the U.S. has propelled the demand of the market. However, the high cost of myeloma therapies and various commodities linked with multiple myeloma drugs has decreased the demand of the multiple myeloma drugs market.
Multiple Myeloma Drugs Market Scenario
According to Data Bridge Market Research, the market for multiple myeloma drugs in the U.S. is growing with market leader namely Bristol-Myers Squibb Company which accounts an estimated market shares of approximately 20% to 25%. The company has gained outstanding sale by providing branded products for multiple myeloma drugs.
- In September 2020, Bristol-Myers Squibb Company had announced that the FDA had accepted the approval for Priority Review their Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121), the companies’ investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of adult patients with multiple myeloma. The initiative by the company would result in swift distribution of the drug in diagnostics center in the U.S., rise in sales and it would deliver a positive growth in the market.
Trends Impacting the Multiple Myeloma Drugs Market
Now the question is which other regions Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited are targeting? Data Bridge Market Research has forecasted a large growth in the U.S. multiple myeloma drugs market to be their next revenue pocket for 2021.
The multiple myeloma drugs market is becoming more competitive every year with companies such as Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited as they are the market leaders for multiple myeloma drugs. The Data Bridge Market Research new reports highlight the major growth factors and opportunities in the U.S. multiple myeloma drugs market.
For more analysis on the U.S. multiple myeloma drugs market, request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=us-multiple-myeloma-drugs-market
New Multiple Myeloma Drugs Market Development
- In December 2020, Janssen Pharmaceuticals, Inc. had proclaimed the proposal of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy to cure refractory multiple myeloma in Raritan New Jersey. The license submitted by the company would result in collaboration between various R&D teams, it would enhance the process of clinical trials, result in rapid distribution of the monoclonal antibodies across hospitals, diagnostic centers and it would exhibit a positive growth in the market.
Scope of the U.S. Multiple Myeloma Drugs Market
All country based analysis of the U.S. multiple myeloma drugs market is further analyzed based on maximum granularity into further segmentation. On the basis of type, the multiple myeloma drugs market is segmented into active (symptomatic) multiple myeloma and smouldering (indolent) multiple myeloma. On the basis of therapy, the multiple myeloma drugs market is segmented into immunotherapy, chemotherapy, corticosteroids and others. On the basis of mechanism of action, the multiple myeloma drugs market is segmented into proteasome inhibitor, monoclonal antibodies, immunomodulatory agents, histone deacetylase inhibitors and others. On the basis of brands, the multiple myeloma drugs market is segmented into darzalex, ninlaro, revlimid, velcade, empliciti, venclexta and others. On the basis of drug type, the multiple myeloma drugs market is segmented into branded and generic. On the basis of route of administration, the multiple myeloma drugs market is segmented into intravenous, oral, subcutaneous, intramuscular, intra-arterial and others. On the basis of end user, the multiple myeloma drugs market is segmented into hospitals, specialty clinics, homecare and others. On the basis of distribution channel, the multiple myeloma diagnostic market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
To know more about the study https://www.databridgemarketresearch.com/reports/us-multiple-myeloma-drugs-market
Key Pointers Covered in the U.S. Multiple Myeloma Drugs Market Industry Trends and Forecast to 2028
- Market Size
- Top to Bottom Market Analysis
- Recent Developments for Market Competitors
- Recent Market Value for Different Countries
- Market Value and Over View of Multiple Myeloma Drugs
- Company Profiling of Top Fifteen Players of Multiple Myeloma Drugs
Key Market Competitors Covered in the Report
- Karyopharm
- Bristol-Myers Squibb Company
- AstraZeneca
- Novartis AG
- GlaxoSmithKline plc
- AbbVie Inc.
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Dr. Reddy’s Laboratories Ltd.
- OncoPep, Inc.
- sanofi-aventis U.S. LLC (a subsidiary of Sanofi)
- Amgen Inc.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Above are the key players covered in the report, to know about more and exhaustive list of multiple myeloma drugs companies’, contact us https://www.databridgemarketresearch.com/toc/?dbmr=us-multiple-myeloma-drugs-market
Research Methodology: U.S. Multiple Myeloma Drugs Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
- Demand Side: Neurologists, Doctors, Healthcare Professionals, Oncologists and Cancer Therapists
- Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence and Regulatory Affairs Managers among others.
Related Reports
- Global Multiple Myeloma Market - Industry Trends and Forecast to 2027
- Global Cancer Immunotherapy Market, - Industry Trends and Forecast to 2027
- Global Topical Corticosteroids Market - Industry Trends and Forecast to 2026
Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/
